Tests SynKIR-110 cell therapy in advanced ovarian cancer, bile duct cancer, or mesothelioma
Tests SynKIR-110, a patient's own modified T cells, in adults with advanced mesothelin-expressing cancers.
Plain-language title generated from the registry record
Registry title: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Key facts
- Where
- Houston, Madison, Philadelphia, Tampa, and Westwood, United StatesSee the 5 sites
- Phase
- Phase 1
Where in United States
- MD Anderson Cancer CenterHouston, United StatesTaking people
- University of Wisconsin Carbone Cancer CenterMadison, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- University of Kansas Cancer CenterWestwood, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verismo Therapeutics
- Trial code
- NCT05568680
- Record updated
- 24 June 2026
- Original description
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.Read full original descriptionShow less
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Inclusion: Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease; Adult 18 years of age or older; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma; Satisfactory Blood coagulation parameters; Satisfactory organ and bone marrow function.
Exclusion: History of T or B cell malignancies or previous gene-engineered T cell therapies; Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years; Have acquired hereditary, congenital immunodeficiency or have recognized immunodeficiency disease; Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening; Active autoimmune disease; Sarcomatoid/biphasic mesothelioma; Pulmonary exclusions.